News

Wanbury’s Patalganga manufacturing facility clear US FDA inspection with zero observations

Wanbury exports APIs to more than 70 countries including the US, Europe and Latin America

Pharma company Wanbury, having a presence in the API global market and domestic branded formulation announced the successful completion of the United States Food & Drug Administration (US FDA) inspection at the Patalganga site, Maharashtra. The inspection was concluded with zero-483 observations.

Mohan Rayana, Director, Wanbury said, “We are pleased to announce the successful completion of the US FDA inspection at our Patalganga site, resulting in zero Form 483 observations. This achievement underscores our commitment to the highest quality and compliance standards at both our API manufacturing sites in Patalganga, Maharashtra, and Tanuku, Andhra Pradesh, both of which are US FDA approved.” 

Wanbury exports APIs to more than 70 countries including the US, Europe and Latin America.

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close